edaravone has been researched along with CACH Syndrome in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Edaravone treatment reduced differential VWMD protein expression of the UPR, phagosome regulation, ubiquitination, autophagy, ER stress, senescence, and TCA cycle pathways." | 1.91 | Edaravone and mitochondrial transfer as potential therapeutics for vanishing white matter disease astrocyte dysfunction. ( Carroll, L; Chung, J; Maksour, S; Newbery, M; Ng, NS; Ooi, L; Touffu, A; Wu, Y; Zaw, T, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ng, NS | 1 |
| Newbery, M | 1 |
| Touffu, A | 1 |
| Maksour, S | 1 |
| Chung, J | 1 |
| Carroll, L | 1 |
| Zaw, T | 1 |
| Wu, Y | 1 |
| Ooi, L | 1 |
1 other study available for edaravone and CACH Syndrome
| Article | Year |
|---|---|
Edaravone and mitochondrial transfer as potential therapeutics for vanishing white matter disease astrocyte dysfunction.
Topics: Astrocytes; Edaravone; Eukaryotic Initiation Factor-2; Humans; Leukoencephalopathies; Mitochondria; | 2023 |